A lipidologist perspective of global lipid guidelines and recommendations, part 2: Lipid treatment goals

被引:4
作者
Bays, Harold E. [1 ]
机构
[1] Louisville Metab & Atherosclerosis Res Ctr Inc, 3288 Illinois Ave, Louisville, KY 40213 USA
关键词
Low-density lipoprotein cholesterol; Guidelines; Lipid goals; Recommendations; Atherosclerotic cardiovascular disease risk; CORONARY-HEART-DISEASE; LOW-DENSITY-LIPOPROTEIN; PATIENT-CENTERED MANAGEMENT; ACUTE MYOCARDIAL-INFARCTION; EARLY STATIN TREATMENT; ADULT TREATMENT PANEL; CARDIOVASCULAR-DISEASE; CHOLESTEROL LEVELS; PRIMARY-PREVENTION; SECONDARY PREVENTION;
D O I
10.1016/j.jacl.2015.11.006
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Having knowledge of worldwide areas of harmonization and consensus regarding lipid guidelines and recommendations may provide clinicians a more global perspective on lipid management. This review examines 8 international scientific/medical organizations that have issued lipid guidelines, recommendations, and position papers: the National Lipid Association (2014), National Institute for Health and Care Excellence (2014), International Atherosclerosis Society (2013), American College of Cardiology/American Heart Association (2013), Canadian Cardiovascular Society (2013), Japan Atherosclerosis Society (2012), European Society of Cardiology/European Atherosclerosis Society (2012), and Adult Treatment Panel III (2001/2004). Part 1 of this perspective focused on sentinel components of these lipid guidelines and recommendations as applied to the role of atherogenic lipoprotein cholesterol levels, primary lipid target of therapy, other primary and secondary lipid treatment targets, and assessment of atherosclerotic cardiovascular disease (ASCVD) risk. This part 2 examines goals of lipid-altering therapy. While lipid guidelines and recommendations may differ regarding ASCVD risk assessment and lipid treatment goals, lipid guidelines and recommendations generally agree on the need to reduce atherogenic lipoprotein cholesterol levels, with statins being the first-line treatment of choice. (C) 2016 National Lipid Association. All rights reserved.
引用
收藏
页码:240 / 264
页数:25
相关论文
共 113 条
  • [61] Intensive lipid lowering with atorvastatin in patients with stable coronary disease
    LaRosa, JC
    Grundy, SM
    Waters, DD
    Shear, C
    Barter, P
    Fruchart, J
    Gotto, AM
    Greten, H
    Kastelein, JJP
    Shepherd, J
    Wenger, NK
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (14) : 1425 - 1435
  • [62] Effect of statins on risk of coronary disease - A meta-analysis of randomized controlled trials
    LaRosa, JC
    He, J
    Vupputuri, S
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 282 (24): : 2340 - 2346
  • [63] Safety and efficacy of atorvastatin-induced very low-density lipoprotein cholesterol levels in patients with coronary heart disease (a post hoc analysis of the treating to new targets [TNT] study)
    LaRosa, John C.
    Grundy, Scott M.
    Kastelein, John J. P.
    Kostis, John B.
    Greten, Heiner
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 2007, 100 (05) : 747 - 752
  • [64] MARTIN MJ, 1986, LANCET, V2, P933
  • [65] LDL Cholesterol:The Lower the Better
    Martin, Seth S.
    Blumenthal, Roger S.
    Miller, Michael
    [J]. MEDICAL CLINICS OF NORTH AMERICA, 2012, 96 (01) : 13 - +
  • [66] The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials
    Mihaylova, B.
    Emberson, J.
    Blackwell, L.
    Keech, A.
    Simes, J.
    Barnes, E. H.
    Voysey, M.
    Gray, A.
    Collins, R.
    Baigent, C.
    de Lemos, J.
    Braunwald, E.
    Blazing, M.
    Murphy, S.
    Downs, J. R.
    Gotto, A.
    Clearfield, M.
    Holdaas, H.
    Gordon, D.
    Davis, B.
    Koren, M.
    Dahlof, B.
    Poulter, N.
    Sever, P.
    Knopp, R. H.
    Fellstrom, B.
    Holdaas, H.
    Jardine, A.
    Schmieder, R.
    Zannad, F.
    Goldbourt, U.
    Kaplinsky, E.
    Colhoun, H. M.
    Betteridge, D. J.
    Durrington, P. N.
    Hitman, G. A.
    Fuller, J.
    Neil, A.
    Wanner, C.
    Krane, V.
    Sacks, F.
    Moye, L.
    Pfeffer, M.
    Hawkins, C. M.
    Braunwald, E.
    Kjekshus, J.
    Wedel, H.
    Wikstrand, J.
    Barter, P.
    Keech, A.
    [J]. LANCET, 2012, 380 (9841) : 581 - 590
  • [67] Primary Prevention of Cardiovascular Mortality and Events With Statin Treatments
    Mills, Edward J.
    Rachlis, Beth
    Wu, Ping
    Devereaux, Philip J.
    Arora, Paul
    Perri, Dan
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2008, 52 (22) : 1769 - 1781
  • [68] Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial
    Nakamura, Haruo
    Arakawa, Kikuo
    Itakura, Hiroshige
    Kitabatake, Akira
    Goto, Yoshio
    Toyota, Takayoshi
    Nakaya, Noriaki
    Nishimoto, Shoji
    Muranaka, Masaharu
    Yamamoto, Akira
    Mizuno, Kyoichi
    Ohashi, Yasuo
    [J]. LANCET, 2006, 368 (9542) : 1155 - 1163
  • [69] National Clinical Guideline Centre (UK), 2014, Lipid Modification: Cardiovascular Risk Assessment and the Modification of Blood Lipids for the Primary and Secondary Prevention of Cardiovascular Disease
  • [70] Effect of Two Intensive Statin Regimens on Progression of Coronary Disease
    Nicholls, Stephen J.
    Ballantyne, Christie M.
    Barter, Philip J.
    Chapman, M. John
    Erbel, Raimund M.
    Libby, Peter
    Raichlen, Joel S.
    Uno, Kiyoko
    Borgman, Marilyn
    Wolski, Kathy
    Nissen, Steven E.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (22) : 2078 - 2087